Thu, September 15, 2011
Wed, September 14, 2011
Tue, September 13, 2011
Mon, September 12, 2011
Sun, September 11, 2011
Sat, September 10, 2011
Fri, September 9, 2011
Thu, September 8, 2011
Wed, September 7, 2011
Tue, September 6, 2011
Mon, September 5, 2011
Sun, September 4, 2011
Sat, September 3, 2011
Fri, September 2, 2011
Thu, September 1, 2011
Wed, August 31, 2011
Tue, August 30, 2011
[ Tue, Aug 30th 2011 ] - Market Wire
00 a.m. ET
Mon, August 29, 2011
Fri, August 26, 2011
Thu, August 25, 2011
Wed, August 24, 2011
Tue, August 23, 2011
Mon, August 22, 2011
Sat, August 20, 2011
Fri, August 19, 2011
Thu, August 18, 2011
Wed, August 17, 2011
[ Wed, Aug 17th 2011 ] - Market Wire
PPD???????BioDuro?????
Tue, August 16, 2011
Mon, August 15, 2011
Fri, August 12, 2011
Thu, August 11, 2011

AVEO Pharmaceuticals, Inc. to Present at Upcoming Investment Conferences


//health-fitness.news-articles.net/content/2011/ .. -present-at-upcoming-investment-conferences.html
Published in Health and Fitness on Wednesday, August 31st 2011 at 4:06 GMT by Market Wire   Print publication without navigation


CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that the companya™s management will present a company overview at upcoming investment conferences.

David Johnston, chief financial officer, is scheduled to present at the William Blair 2011 Life Sciences Conference on Wednesday, September 7, 2011 at 2:00 p.m. (EDT) at the InterContinental New York Barclay in New York City.

Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the UBS Global Life Sciences Conference on Monday, September 19, 2011 at 4:30 p.m. (EDT) at the Grand Hyatt in New York City.

Webcasts of AVEOa™s presentations can be accessed by visiting the investors section of the companya™s website at investor.aveopharma.com. A replay of the webcasts will be archived on the AVEO website for two weeks following each presentation date, respectively.

About AVEO

AVEO Pharmaceuticals (NASDAQ: AVEO) is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies to impact patientsa™ lives. The companya™s lead product candidate, tivozanib, is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in patients with advanced renal cell carcinoma, as well as additional clinical studies in other solid tumor types. AVEOa™s second most advanced product candidate, ficlatuzumab (AV-299), is a potent, functional anti-HGF/c-MET pathway antibody that is currently in Phase 2 clinical development. AVEOa™s proprietary Human Response Platforma" is designed to offer the company a unique advantage in cancer drug development and has provided a discovery engine for multiple therapeutic targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets including HGF, ErbB3, RON, Notch and FGFR. For more information, please visit the companya™s website at www.aveopharma.com.


Publication Contributing Sources